FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies by CNBC Markets | April 30, 2026 9:25 pm | US Markets If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA’s drug shortage list.
